SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
SEELAS Life Sciences (SLS) Newsfilter·2024-07-16 21:05- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS' Second RPDD Following the Designation for ALL Received Last Month - - Opened Enrollment for Pediatric AML Patients in Ongoing Phase 2 Clinical Trial - - RPDD Provides Eligibility for SLS009 to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be Transferred/Sold to Other Parties – NEW ...